UBS assumed coverage of Denali Therapeutics (DNLI) with a Buy rating and a price target of $25, up from $24, as the analyst initiated or assumed coverage on 22 small-to-mid cap biotech names. After a rough period, biotech fundamentals are now inflecting, contends the analyst, who expects investor confidence to recover and sees this positioning biotech for strong performance in 2026.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DNLI:
- Denali Therapeutics Sets 2026 Priorities Ahead of Tividenofusp Decision
- Denali Therapeutics announces key milestones, priorities for 2026
- Denali Therapeutics announces publication of Phase 1/2 study of DNL310
- Denali Therapeutics price target lowered to $30 from $31 at Wedbush
- Denali Therapeutics Announces $200M Public Offering